Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression

【24h】

Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression

机译：PAM50内在亚型分布在来自CTC-MBC试验中的匹配的主要和转移性乳腺癌样品中的副型亚型谱（NCT01322893）显示出在肿瘤进展中更具侵袭性亚型的显着变化

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：PAM50内在亚型分布在来自CTC-MBC试验中的匹配的主要和转移性乳腺癌样品中的副型亚型谱（NCT01322893）显示出在肿瘤进展中更具侵袭性亚型的显着变化
2. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer [J] . Cejalvo Juan M., de Duenas Eduardo Martinez, Galvan Patricia, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2017,第9期

机译：原发性乳腺癌中的内在亚型和基因表达谱
3. PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial [J] . Prat A., Brase J. C., Cheng Y., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：PAM50在激素受体阳性（HR Plus）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）中的蛋白质亚型（EXE）与Everolimus（EVE）或安慰剂（PBO）组合处理： III阶段Bolero-2试验的相关分析
4. Quantitative diffusion weighted imaging parameters in tumor and peritumoral stroma for prediction of molecular subtypes in breast cancer [C] . Ting He, Ming Fan, Peng Zhang, SPIE Medical Imaging Conference . 2018

机译：肿瘤和肿瘤周围基质中定量扩散加权成像参数预测乳腺癌分子亚型
5. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer [O] . Juan M. Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, -1

机译：原发性和转移性乳腺癌的内在亚型和基因表达谱
6. 180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial [O] . E.M. Ciruelos, P. Villagrasa, M. Oliveira, 2020

机译：180tip Palbociclib，Trastuzumab和内分泌治疗（ET）与METSICIAN的选择（TPC）治疗转移性HER2-阳性和激素受体阳性（HER2 + / HR +）乳腺癌（BC）用PAM50腔内在亚型（Solti-1303 Patricia II）：随机期二期试验

Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression

著录项

相似文献

相关主题

期刊订阅